iSpecimen Q2 revenue up 76% to $2.86M; net loss narrows to $2.11M

iSpecimen Inc.

2024-Q2 EPS reported -$0.49 vs consensus -$228.48 ▲ beat (+99.8%)

Revenue $2.86M (+76% YoY); net loss $2.11M ($0.19/sh) vs $3.5M loss ($0.39/sh) in Q2 2023.
Hired Brielan Smiechowski as SVP of Sales & Business Development.
Next Day Quotes conversion rate 58% to purchase orders.
Cash and securities $2.15M as of June 30, 2024, down from $5.01M at Dec 31, 2023.
Supplier organizations reduced to 105 from 243 at year-end 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.